Value-based care in Swiss hospitals: a working paper

Value-based care keeps failing to cross the Atlantic. The problem is not Swiss reluctance; it is a category error about where value can actually be captured in a DRG system.

The stalled ambition

Value-based care, the principle that providers should be rewarded for the outcomes they produce rather than the activity they perform, has been a stated ambition of Swiss health policy for over a decade. Implementation has been slow, fragmented and confined to pilots whose results have not generalised. The conventional diagnosis is cultural: the Swiss system is conservative, federal, slow to move. This paper argues the diagnosis is wrong. The problem is a category error. The dominant value-based care frameworks were designed for the integrated American payer-provider, and they do not map onto the Swiss DRG-plus-supplementary-insurance model. Importing them unadapted produces exactly what Switzerland has: a decade of conferences and a handful of stranded pilots.

The underlying idea deserves better than its imports. Porter's formulation remains the cleanest: value is health outcomes achieved per franc spent, measured over the full cycle of care for a patient's condition, not the volume of services delivered (Porter, 2010). Nothing in that definition requires an American contract structure. What requires the American contract structure is the standard implementation, and that is the part that fails here.

The Swiss starting position

Swiss acute care has been funded through a national Diagnosis-Related Group system, SwissDRG, since 2012: the episode is priced prospectively, with mandatory health insurance providing the base layer and supplementary insurance covering amenity and choice. Outcomes data exists, notably the ANQ national quality indicators and a growing set of clinical registries, but it is structurally decoupled from payment. Cantonal sovereignty over hospital planning fragments both the provider landscape and the data needed to compare it.

This starting position is not a deficiency to be corrected before value-based care can begin. It is the terrain, and any model that requires the terrain to change first is not a model; it is a wish.

Why imported value-based care fails here

Three structural mismatches recur in every stalled Swiss initiative we have examined.

There is no single accountable counterparty. The American constructs, accountable care organisations, bundled-payment contracts, capitated networks, all presume an entity that can sign for the whole cycle of care and carry its risk. In the Swiss configuration the episode's cost and consequences are split across hospital, cantonal planner, mandatory insurer, supplementary insurer and downstream providers, none of whom can contract for the whole.

The episode is already priced. SwissDRG prices the inpatient episode prospectively. Outcome-linked payment on top of it means either supplementing the tariff or replacing it, and both routes run through national tariff politics, which is precisely where pilots go to die.

The comparison data is fragmented. Meaningful outcome payment requires risk adjustment across comparable populations. Cantonal fragmentation of planning and records makes the required dataset a multi-year federal project in itself, and conditioning value-based care on its completion defers the ambition indefinitely.

The pattern in all three is the same: the imported models locate value capture in the contract, and the Swiss system has no place to put such a contract.

Relocating value capture: the pathway, not the contract

Our working position is that in a DRG system the workable unit of value capture is the clinical pathway, inside the institution, rather than the payment contract outside it.

Hospitals already own their pathways. A hip replacement, a colorectal resection, a heart-failure admission: each has a definable start, a definable cycle of care and measurable outcomes, which is exactly the condition-level framing the value definition requires (Porter, 2010). None of it needs a tariff renegotiation to manage.

The model, concretely: pathway-level outcome definitions agreed with the relevant medical society rather than the payer, so the measures carry clinical authority; a pathway outcome dashboard owned by the chief medical officer and reviewed quarterly with department heads, in a forum where the outcomes are debated by clinicians rather than presented to them; and a real-time data flow from the clinical systems to the pathway owner that does not queue behind the finance department's reporting calendar.

What this generates is the accountability that value-based contracts attempt to purchase externally, produced internally instead. The hospital that runs it captures value twice: clinically, because pathway variation surfaces and closes, and economically, because within a fixed DRG price every avoided complication and every day of length-of-stay reduction accrues to the institution. The DRG system, so often described as the obstacle to value-based care, becomes its quiet enabler: a fixed price turns internal outcome improvement directly into margin.

What this requires, and what it does not

It requires pathway-level outcome definitions with medical-society legitimacy, a data flow the pathway owner controls, and a governance rhythm that treats per-pathway outcomes as seriously as the aggregate P&L. It requires the chief medical officer to own a number, which is a larger cultural step than it sounds.

It does not require new federal legislation, tariff reform, a cantonal data union or the invention of a Swiss accountable care organisation. That is the point. Every element is within the authority of a single hospital board, which means the model can start on Monday and be judged on evidence within a year.

The payer is not excluded from this picture; it is re-sequenced. A hospital that has run pathway-level value internally for two years holds exactly the outcome data with which selective, condition-level agreements with insurers become negotiable from strength. Contract-level value-based care, in other words, is the eventual consequence of pathway mastery, not the precondition for it.

Open questions

This is a working paper in the honest sense: a position we hold with confidence and publish in order to have it tested. The open questions we consider live are these. Which pathways yield the fastest demonstrable value, surgical pathways with clean cycles, or chronic admissions where the variation is larger and messier? Where should patient-reported outcomes enter the dashboard without drowning the clinical measures? And at what point does the internal model hit its ceiling, such that tariff-level instruments become necessary after all?

Reader challenges, counter-evidence and disagreement are welcome and will be incorporated into the next revision. That is what a working paper is for.

References

1. Porter, M.E. (2010) 'What is value in health care?', New England Journal of Medicine, 363(26), pp. 2477-2481. https://doi.org/10.1056/NEJMp1011024